1.
Fachinformation Opdivo® (Nivolumab); Stand: Mai 2016.
2.
Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
3.
Meier C, Garbe C: Medikamentöse Therapie in Stadium IV; in S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms, Version 2.0 - Juli 2016; AWMF-Register-Nummer: 032/024OL.
4.
Postow MA, Callahan MK, Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-1982.
5.
Fachinformation Yervoy® (Ipilimumab); Stand: April 2016.
6.
Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
7.
Schadendorf D, Hodi FS, Robert C, et al: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889-1894.
8.
Schilling B, Weide B: Immuntherapie im Stadium IV; in S3-Leitlinie zur diagnostik, Therapie und Nachsorge des Melanoms, Version 2.0 - Juli 2016; AWMF-Register-Nummer: 032/024OL.
9.
Dong H, Zhu G, Tamada K, Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-1369.
10.
Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-1034.
11.
Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-1030.
12.
Hodi FS, Kluger HM, Sznol M, et al: Durable, long-term survival in previously treated patients with advanced melanoma who received nivolumab monotherapy in a phase I trial. AACR Annual Meeting 2016; abstr CT001.
13.
Robert C, Long G, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-323.
14.
Atkinson A, Ascierto PA, Long GV, et al: Two-year survival and safety update in patients with treatment-naïve advanced melanoma (MEL) receiving nivolumab or dacarbazine in CheckMate 066. Poster beim SMR-Kongress 2015, San Francisco, CA, USA.
15.
Okazaki T, Chikuma S, Iwai Y, et al: A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013;14:1212-1218.
16.
Curran MA, Montalvo W, Yagita H, et al: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275-4280.
17.
Selby M, Englehardt J, Lu L-S, et al: Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J Clin Oncol 2013;31(suppl):3061.
18.
Larkin J, Chiarion‑Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
19.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al: Updated results from a phase III trial of nivolumab combined with ipilimumab in treatment-naïve patients with advanced melanoma (CheckMate 067). J Clin Oncol 2016;34(suppl):abstr 9505.
20.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Efficacy and safety in key patient subgroups of nivolumab alone or combined with ipilimumab versus ipilimumab alone in treatment-naïve patients with advanced melanoma (CheckMate 067). ECCO 2015;abstr 3303.
21.
Czeschik C: Initiale Ausbreitungsdiagnostik - S100B, MIA, LDH; in S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms, Version 2.0 - Juli 2016; AWMF-Register-Nummer: 032/024OL.
22.
Topalian SL, Taube JM, Anders RA, et al: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev 2016;16:275-287.
23.
Postow MA, Chesney J, Pavlick AC, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-2017.
24.
Postow MA, Chesney J, Pavlick AC, et al: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab and ipilimumab in patients with advanced melanoma. AACR Annual Meeting 2016;abstr CT002.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently...
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.